Ready-to-administer injectables

B. Braun Melsungen AG completes acquisition of Sterinova Inc.

Saint-Hyacinthe, QC – September 29, 2021 – B. Braun Melsungen AG announces that it has acquired the minority interest of the cofounders Jean-Philippe Gentes and Bertrand Bolduc in Sterinova Inc. and now owns 100% of the company. Sterinova will continue to operate as a distinct subsidiary of B. Braun Melsungen AG.

“We thank the founders for their work for Sterinova since the inception of the company and wish them all the best in their future projects” said Dr. Meinrad Lugan, Member of the Board of B. Braun Melsungen AG.

About B. Braun

With over 64,000 employees in 64 countries, the family-owned company B. Braun is one of the world’s leading suppliers of solutions for the healthcare market and provides users and patients with products and product systems for anesthesia, intensive care, cardiology, extracorporeal blood treatment, surgery or home care, as well as services for hospitals and general practitioners. In 2020, the Group generated sales of €7.4 billion.

About Sterinova Inc.

Based in St-Hyacinthe, Quebec, Sterinova develops, manufactures and distributes ready-to-use sterile injectable products in syringes and premix bags. Founded in 2012, the company meets the rigorous standards required by the guidelines of Good Manufacturing Practices (GMP).

– 30 –